[
  {
    "ts": null,
    "headline": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
    "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
    "url": "https://finnhub.io/api/news?id=eb9505c9f5e354b3b6eeb6affd67156d88e0d5832f9c41472c2cbfa42b650038",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612880,
      "headline": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
      "id": 138281541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
      "url": "https://finnhub.io/api/news?id=eb9505c9f5e354b3b6eeb6affd67156d88e0d5832f9c41472c2cbfa42b650038"
    }
  },
  {
    "ts": null,
    "headline": "Abbot (ABT) is a High Quality Company, Says Jim Cramer",
    "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. Abbott Laboratories (NYSE:ABT) is one of the stocks on Jim Cramer’s radar. Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. […]",
    "url": "https://finnhub.io/api/news?id=0a926e279f0959288cf7f2ec68bff74dcb0cc1144a0e71c239840f501c2e25b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611899,
      "headline": "Abbot (ABT) is a High Quality Company, Says Jim Cramer",
      "id": 138281542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. Abbott Laboratories (NYSE:ABT) is one of the stocks on Jim Cramer’s radar. Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. […]",
      "url": "https://finnhub.io/api/news?id=0a926e279f0959288cf7f2ec68bff74dcb0cc1144a0e71c239840f501c2e25b3"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares.",
    "summary": "Shares of  Abbott Laboratories  suffered their worst drop in more than 20 years following Abbott’s fourth-quarter earnings report.  A Form 4 filed with the Securities and Exchange Commission earlier this week shows CEO Robert Ford bought 18,800 shares for roughly $107.13 each, or $2 million in total, on Friday.  The shares are held in a family trust, of which Ford is a co-trustee, meaning he counts them among 216,203 shares he owns indirectly.",
    "url": "https://finnhub.io/api/news?id=e14c3ba4a01f3842d382ea2163ccc21dd7e9272af324af9316f36b434ab7f04e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611680,
      "headline": "Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares.",
      "id": 138285162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Shares of  Abbott Laboratories  suffered their worst drop in more than 20 years following Abbott’s fourth-quarter earnings report.  A Form 4 filed with the Securities and Exchange Commission earlier this week shows CEO Robert Ford bought 18,800 shares for roughly $107.13 each, or $2 million in total, on Friday.  The shares are held in a family trust, of which Ford is a co-trustee, meaning he counts them among 216,203 shares he owns indirectly.",
      "url": "https://finnhub.io/api/news?id=e14c3ba4a01f3842d382ea2163ccc21dd7e9272af324af9316f36b434ab7f04e"
    }
  },
  {
    "ts": null,
    "headline": "Medtech M&A took off in the second half of 2025: report",
    "summary": "Acquisitions and spinoffs in 2025 surpassed the previous three years, according to a report from Bain & Company.",
    "url": "https://finnhub.io/api/news?id=07cda2a558b240a6fd74620d80e2bb240e85b771d3fc647258731dd3702e10a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769600763,
      "headline": "Medtech M&A took off in the second half of 2025: report",
      "id": 138285163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Acquisitions and spinoffs in 2025 surpassed the previous three years, according to a report from Bain & Company.",
      "url": "https://finnhub.io/api/news?id=07cda2a558b240a6fd74620d80e2bb240e85b771d3fc647258731dd3702e10a3"
    }
  }
]